West Pharmaceutical Services (WST) has seen its share price decline about 16% over the past month, despite a favorable Zacks Rank of #2 (Buy) and analysts raising earnings estimates. The company reported $2.89 billion in net sales for fiscal year 2024 and is currently trading at a 50% discount to analyst price targets, indicating significant potential for recovery. As WST prepares to release its fourth-quarter and full-year 2025 results on February 12, 2026, investors remain focused on its strong market position in injectable drug administration solutions.
“West Pharmaceutical Services · has · Zacks Rank · #2 (Buy)”
“West Pharmaceutical Services · has · forward P/E ratio · 31.34”
“West Pharmaceutical Services · has · PEG ratio · 3.31”
“West Pharmaceutical Services · has · P/B ratio · 5.67”
“West Pharmaceutical Services · holds · Value grade · C”
“West Pharmaceutical Services · is · a manufacturer of specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products · true”
“West Pharmaceutical Services · has a Trailing 12-Month Free Cash Flow Margin of · 12.6% · true”
“West Pharmaceutical Services (WST) · has lost · 6.1% · over the past week”
“Wall Street analysts · are in strong agreement · raising earnings estimates · for WST”
“WST · currently has · a Zacks Rank #2 (Buy) · which means it is in the top 20% of more than 4,000 stocks”
“a Zacks Rank of 2 for West Pharmaceutical · is a more conclusive indication of · a potential trend reversal”
“West Pharmaceutical Services (WST) · has been drawing attention after recent trading pressure · share price down around 16% · over the past month”